Source: Frontiers in Pharmacology. Unidades: FCF, ICB, BIOTECNOLOGIA
Subjects: PARASITOLOGIA, MICROBIOLOGIA, COVID-19, INIBIDORES DE ENZIMAS, DOENÇAS RESPIRATÓRIAS, ANGIOTENSINA II, SISTEMA RENINA-ANGIOTENSINA, ANTIVIRAIS, CAMUNDONGOS, MODELOS ANIMAIS DE DOENÇAS
ABNT
SANTOS, Yasmin Silva et al. Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19. Frontiers in Pharmacology, v. 15, 2024Tradução . . Disponível em: https://doi.org/10.3389/fphar.2024.1414406. Acesso em: 17 nov. 2024.APA
Santos, Y. S., Gamon, T. H. M., Azevedo, M. S. P. de, Bielavsky, M., Darido, M. L. G., Oliveira, D. B. L. de, et al. (2024). Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19. Frontiers in Pharmacology, 15. doi:10.3389/fphar.2024.1414406NLM
Santos YS, Gamon THM, Azevedo MSP de, Bielavsky M, Darido MLG, Oliveira DBL de, Souza EE de, Luvizotto MCR, Ackerman HC, Carvalho LJ de M, Epiphanio S, Wrenger C, Durigon EL, Marinho CRF. Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19 [Internet]. Frontiers in Pharmacology. 2024 ; 15[citado 2024 nov. 17 ] Available from: https://doi.org/10.3389/fphar.2024.1414406Vancouver
Santos YS, Gamon THM, Azevedo MSP de, Bielavsky M, Darido MLG, Oliveira DBL de, Souza EE de, Luvizotto MCR, Ackerman HC, Carvalho LJ de M, Epiphanio S, Wrenger C, Durigon EL, Marinho CRF. Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19 [Internet]. Frontiers in Pharmacology. 2024 ; 15[citado 2024 nov. 17 ] Available from: https://doi.org/10.3389/fphar.2024.1414406